The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes
Study Details
Study Description
Brief Summary
To assess the efficacy of the REST model in facilitating adoption and sustained use of CGM, in older adults with Type 1 diabetes (T1D) or Type 2 Diabetes (T2D) on complex insulin regimens. To examine barriers and enablers for the implementation feasibility of the REST intervention model using a mixed-methods approach. To assess the impact of REST model on economic factors and quality of life measures. The goal of this study is to facilitate the adoption of continuous glucose monitoring (CGM) in older adults (≥65 years) with diabetes mellitus (DM) on complex insulin regimens, and additionally, to build a framework for sustained CGM use over time using a novel patient-centered model - the REST model.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Older adults with diabetes on multiple insulin injections are at greater risk of hypoglycemia and its poor outcomes. Use of continuous glucose monitoring (CGM) has shown to improve glycemic control and reduce hypoglycemia in this age group. Despite Medicare coverage for CGM, uptake in this age group is still low. The goal of this study is to facilitate the adoption of continuous glucose monitoring (CGM) in older adults (≥65 years) with diabetes mellitus (DM) on complex insulin regimens, and additionally, to build a framework for sustained CGM use over time using a novel patient-centered model - the REST model. This model will assess Readiness and barriers to CGM initiation and utilization, provide remote Education, and implement a framework for Sustainability of CGM Technology adoption. The study will assess the impact of the REST model and its ability to increase CGM uptake and use in this age group, as well as its effectiveness on improving glycemic metrics. The study will also evaluate the impact of the REST model on economic and health-related quality-of-life measures.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Single Arm
|
Device: Continuous Glucose Monitor
Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The co-primary effectiveness outcomes [Baseline to 6 months]
Change in time spent in hypoglycemia (sensor glucose <70 mg/dL and ii) Change in individualized Time in Range goal
- The co-primary implementation outcomes [Baseline vs 6 months]
Change in adoption of CGM by remote education (change in number of CGM users and ii) change in number of hours of CGM use per week
Secondary Outcome Measures
- Visits to maintain CGM use [6 months]
Total time spent and the number of remote and in-person visits needed to initiate and maintain CGM use
- Visits to maintain CGM use [Month 12]
Total time spent and the number of remote and in-person visits needed to initiate and maintain CGM use
- Resource utilization [Baseline vs 6 months]
Change in resource utilization (episodes of severe hypoglycemia, emergency department visits, and hospitalizations)
- Resource utilization [6 months vs 12 months]
Change in resource utilization (episodes of severe hypoglycemia, emergency department visits, and hospitalizations)
- Time spent in hypoglycemia [6 months vs 12 months]
Change in time spent in hypoglycemia ( sensor glucose <70 mg/dL)
- Cost effectivness [6 months]
Cost-effectiveness ratios to assess the economic aspects for REST model compared standard of care
- Cost Effectivness [12 months]
Cost-effectiveness ratios to assess the economic aspects for REST model compared standard of care
- Diabetes health related quality of life measures [Baseline vs 6 months]
Change in quality of life measures (diabetes distress, hypoglycemia fear, EQ-5D)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Older adults age ≥65 years
-
T1D or T2D with duration longer than 1 year
-
Insulin treatment includes: ≥3 insulin injections/day or on insulin pump therapy
-
CGM naïve and/or CGM users (Dexcom G6) who are not meeting glycemic goals (per
CGM metrics):
-
≥4% hypoglycemia (sensor glucose ≤70 mg/dL) or
-
time in range (70-180 mg/dL) TIR ≤40 %
-
Willing to wear CGM Dexcom at all times while in the study
-
Willing to use/carry personal or loaned smart phone device to use as Dexcom receiver for continual data upload to cloud
Exclusion Criteria:
-
Life expectancy <1 year
-
End-stage renal disease (eGFR< 30ml/min)
-
On acetaminophen >4 gr/day due to interference with Dexcom G6 sensor readings
-
On hydroxyurea therapy due to interference with Dexcom G6 sensor readings
-
Impaired vision and hearing which would interfere with participation in remote video visits
-
Use of hybrid closed-loop systems (this may require different and additional focused education and will not be addressed in this study).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Joslin Diabetes Center | Boston | Massachusetts | United States | 02215 |
| 2 | SUNY Upstate Medical University | Syracuse | New York | United States | 13210 |
Sponsors and Collaborators
- Joslin Diabetes Center
- State University of New York - Upstate Medical University
- Cecilia Health
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00000174